Biologics Drug / Agent News and Research

RSS

Biologic therapies are changing the way dermatologists treat psoriasis

Recently approved and investigational biologic therapies are changing the way dermatologists treat psoriasis, a chronic disease that physically and emotionally challenges 4.5 million Americans. As more research is conducted into the effectiveness of these biologics, they are showing great promise for improving the health and well-being of patients with psoriasis.

20 Feb 2005

Research leads to new antiangiogenic drugs

Scientists have uncovered critical information that may lead to an urgently needed method for effective monitoring of antiangiogenic cancer therapies.

17 Jan 2005

Promising new evidence for the optimal use of biologic therapies for rheumatoid arthritis

A major cause of pain and disability, rheumatoid arthritis (RA) is also potentially the most treatable form of chronic arthritis. Researchers, doctors, and patients agree that a group of drugs called disease-modifying antirheumatic drugs (DMARDs) can effectively reduce joint pain and stiffness.

7 Jan 2005

Patent issued for generating genetically evolved mammalian cells through the regulation of mismatch repair

Morphotek announced today the issuance of United States Patent 6,825,038 covering the regulation of mismatch repair (MMR), a powerful process for generating functional diversity in mammalian cells, to yield sibs exhibiting desirable phenotypes for target discovery, drug screening and/or product development.

13 Dec 2004

Heart Hospital begins experimental cell therapy

Physicians at the Heart Hospital became the first team in the UK to treat a patient with an experimental new therapy designed to repair damage to cardiac muscle resulting from a heart attack. If successful, this treatment would give doctors the ability to improve the hearts of people with heart failure, rather than just treating the symptoms.

6 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Low level exposure to Benzene causes lower blood cell counts

A new study found that white blood cell counts were lowered in workers exposed to less than 1 ppm of the chemical benzene (part benzene per million parts air).

3 Dec 2004

Astronaut's eyes may become windows on the bloodstream

Our eyes may become more than windows of the soul if a multidisciplinary team of University of Michigan researchers succeeds with a clever combination of nanoparticles and ultrafast pulsed laser to see individual cells as they zip past in the bloodstream.

29 Nov 2004

Avastin plus Folfox4 chemotherapy significantly extends survival in second-line metastatic colorectal cancer

Genentech and Roche today announced that a randomized Phase III study of Avastin™ (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival.

29 Nov 2004

Study links a novel protein pathway to the aggressive progression of breast cancer

Cytogen Corporation today announced the publication of a study linking a novel protein pathway to the aggressive progression of breast cancer.

24 Nov 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Vaccinex and Biocon to co-develop at least four therapeutic antibody products

The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.

19 Nov 2004

Less risks for patients participating in early phase cancer drug trials

The risk of treatment-related (toxic) death for cancer patients enrolled in phase 1 clinical trials had decreased significantly over the past 12 years (from 1991 to 2002), according to an article in the November 3 issue of JAMA.

3 Nov 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004

Cost cutting measures and patent expirations to propel the European generics and biogenerics market

The upcoming spate of patent expirations bodes well for the European generics market. The growing loss of patent protection on blockbuster brands over the next few years, coupled with the rising need to contain spiralling healthcare costs, is set to provide a fillip to market expansion.

19 Oct 2004

Study underscores the relative safety of infliximab, when used properly

Rheumatoid arthritis patients receiving the recommended starting dose (3mg/kg) of infliximab (REMICADE®) have no more serious rate of infections than do patients taking methotrexate alone

18 Oct 2004

Interleukin-6 has potential as a therapeutic drug in treating metabolic disorders such as obesity, type 2 diabetes and atherosclerosis

For the most of the past century, researchers have searched for a muscle-contraction-induced factor, which mediates some of the exercise effects in other tissues and organs such as the liver and adipose tissue.

5 Oct 2004